Published on
August 25, 2022
- 12:43 GMT
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
Ad hoc announcement pursuant to Art. 53 LR Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1 European generics company and a global leader in biosimilars, and …
Distribution channels:
Banking, Finance & Investment Industry
